Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...

Aridis Provides Corporate Update LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on...

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP) LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of...

The Global Pneumonia Therapeutics Market Estimated to Generate a Revenue of $3,147.7 Million by 2027, Growing at a CAGR of 8.2% From 2020-2027 – Informative Report [230 Pages] by Research Dive New York, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global pneumonia therapeutics market is expected to generate a revenue of $3,147.7 million by...

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™Pivotal Trials Planned in...